News & Events

Learn about what's new with CMC Biologics

AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program


(SEATTLE), July 9, 2020 -- Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Biologics and Molecular Partners AG will work together to develop their multi-specific DARPin anti-COVID-19 program, MP0420. Molecular Partners AG plans to initiate clinical studies for this program in the second half of 2020.

AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site


Expansion will help meet the growing demand for plasmid DNA offerings

(SEATTLE), June 30, 2020-- Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) is further expanding to meet the growing need for process development and manufacturing for plasmid DNA (pDNA). The 1M EUR investment in a laboratory build-out includes a significant increase of lab area, additional staffing and state-of-the-art equipment, to foster high-throughput techniques and quality by design processes. This will further expand AGC Biologics’ service portfolio and build on a track record of more than seven years in commercial plasmid manufacturing.

Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing


AGC Biologics produces humanized monoclonal antibody targeting IL-15

(SEATTLE), June 18, 2020 -- AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), produces a GMP-grade clinical batch of CALY-002 for Calypso Biotech. The immunotherapy biotech company retained the services of AGC Biologics for the development of the manufacturing process and the production of its clinical supply.

Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine


AGC Biologics will manufacture SARS-CoV-2 vaccine for partner Saiba AG

(SEATTLE), June 16, 2020 -- AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), has announced it will be partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine.

Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine


AGC Biologics partners with Novavax to produce NVX-CoV2373 component

(SEATTLE), June 3, 2020 -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology. AGC Biologics will optimize process development for scaled-up production of Matrix-M to significantly increase Novavax’ capacity to deliver doses in 2020 and 2021.

AGC Biologics Acquires Commercial Facility, Expanding Global Service Offerings


AGC Biologics acquires Boulder, Colorado U.S.A. facility to increase global capacity and extend manufacturing scale

(SEATTLE), June 1, 2020 -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the purchase of a state-of-the-art commercial manufacturing facility in Boulder, Colorado U.S.A. The facility, formerly owned by AstraZeneca, will provide AGC Biologics with additional capacity and significantly larger production scale. The facility is expected to begin full-scale operations and manufacturing by April 2021.

Boulder, CO Facility-1

Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)


(SEATTLE), May 20, 2020 -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.

AGC Biologics to Participate in First-Ever BIO Digital Conference


(SEATTLE), May 14, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event.  BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine.

AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer Treatment


AGC Biologics will manufacture novel precision cancer immunotherapy treatment Clevegen

(SEATTLE), May 5, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company. Clevegen is a humanized anti-Clever-1 antibody which targets CLEVER-1 positive tumour associated macrophages (TAMs) and converts these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. This unique macrophage-directed immuno-oncology switch may be used alone or in combination with other cancer treatments.

AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab


The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients.  AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.

Vancouver biotech company tests COVID-19 treatment
Follow Us
Join us on LinkedIn Follow us on Twitter